KSR staff publications

2018

Thielen FW, Büyükkaramikli NC, Riemsma RFayter DArmstrong N, Wei CY, Huertas Carrera VMisso KWorthy GKleijnen J, Corro Ramos I. Obinutuzumab in combination with chemotherapy for the first-line treatment of patients with advanced follicular lymphoma: an Evidence Review Group evaluation of the NICE single technology appraisal. Pharmacoeconomics 2018;Epub ahead of print. Full text.

 

Bramer WM, Giustini D, Kleijnen J, Franco OH. Searching Embase and MEDLINE by using only major descriptors or title and abstract fields: a prospective exploratory study. Syst Rev 2018;7(1):200. Full text.

 

Ramaekers BLT, Riemsma R, Grimm S, Fayter D, Deshpande S, Armstrong N, Witlox W, Pouwels X, Duffy SWorthy GKleijnen J, Joore MA. Arsenic trioxide for treating acute promyelocytic leukaemia: an Evidence Review Group perspective of a NICE single technology appraisal. Pharmacoeconomics 2018;Epub ahead of print. Full text.

 

van Erp RMA, Huijnen IPJ, Jakobs MLG, Kleijnen J, Smeets RJEM. Effectiveness of primary care interventions using a biopsychosocial approach in chronic low back pain: a systematic review. Pain Pract 2018;Epub ahead of print. Abstract.

 

Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. [ROBIS: a new tool to assess risk of bias in systematic reviews was developed]. Recenti Prog Med 2018;109(9):421-31. Full text.

 

Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: guida all'uso. Recenti Prog Med 2018;109(9):1e-26e. Full Text.

 

Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: strumento per valutare il rischio di bias nelle revisioni sistematiche. Recenti Prog Med 2018;109(9):27e-29e. Full text.

 

Grimm SE, Armstrong N, Ramaekers BLT, Pouwels X, Lang S, Petersohn S, Riemsma RWorthy GStirk LRoss JKleijnen J, Joore MA. Nivolumab for treating metastatic or unresectable urothelial cancer: an Evidence Review Group perspective of a NICE single technology appraisal. Pharmacoeconomics 2018 Oct 6. doi: 10.1007/s40273-018-0723-5. [Epub ahead of print]. Full text.

 

Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A systematic approach to searching: an efficient and complete method to develop literature searches. Journal of the Medical Library Association 2018;106(4):531-41. Full text.

 

Büyükkaramikli NC, de Groot S, Riemsma RFayter DArmstrong N, Portegijs P, Duffy SKleijnen J, Al MJ. Ribociclib with an aromatase inhibitor for previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer: an Evidence Review Group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018 [Epub ahead of print]. Full text.

 

Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock SArmstrong N, Joore M, Kleijnen J. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment 2018;22(44):1-264. Full text.

 

Kleijnen J. What's up, doc? The latest news on finding reviews. JBI Database of Systematic Reviews and Implementation Reports 2018;16(6):1284-5. Full text.

 

Lang SArmstrong N, Deshpande S, Ramaekers B, Grimm S, de Kock SKleijnen JWestwood ME. ANNALS EXPRESS: Clinically inappropriate post-hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. Annals of Clinical Biochemistry 2018:4563218782722 [Epub ahead of print]. Abstract.

 

Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, Riemsma R, Grimm S, Ramaekers B, Joore M, Büyükkaramikli N, Kaltenthaler E, Stevenson M, Pandor A, Edwards S, Hoyle M, Shepherd J, Armoiry X, Brazzelli M. EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Appl Health Econ Health Policy 2018 May 28. doi: 10.1007/s40258-018-0393-7. [Epub ahead of print] Full text.

van Abbema DL, van den Akker M, Janssen-Heijnen ML, van den Berkmortel F, Hoeben A, de Vos-Geelen J, Buntinx F, Kleijnen J, Tjan-Heijnen VCG. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review. J Geriatr Oncol 2018 Apr 26. pii: S1879-4068(18)30138-3. doi: 10.1016/j.jgo.2018.04.001. [Epub ahead of print]. Full text.
 

Forbes CA, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, Hagström E. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Current Medical Research and Opinion 2018 May 17:1-27. doi: 10.1080/03007995.2018.1477747. [Epub ahead of print]. Abstract.

 

van Tol RR, van Zwietering E, Kleijnen J, Melenhorst J, Stassen LP, Dirksen CD, Breukink SO. Towards a core outcome set for hemorrhoidal disease-a systematic review of outcomes reported in literature. International Journal of Colorectal Disease 2018:[Epub ahead of print]. Full text.

 

Bram L. T. Ramaekers, Robert F. Wolff, Xavier Pouwels, Marije Oosterhoff, Anoukh Van Giessen, Gill WorthyCaro NoakeNigel ArmstrongJos Kleijnen, Manuela A. Joore. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. [Epub ahead of print] PharmacoEconomics (2018). Full text. 

 

Xavier G. L. V. Pouwels, Robert Wolff, Bram L. T. Ramaekers, Anoukh Van Giessen, Shona LangSteve Ryder, Gill Worthy, Steven DuffyNigel ArmstrongJos Kleijnen, Manuela A. Joore. Ticagrelor for Secondary Prevention of Atherothrombotic EventsAfter Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. [Epub ahead of print]. Pharmacoeconomics 2018. Full text.